Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + AT-101 in Relapsed B-CLL
NCT01003769Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jul 2015
- Primary completion
- Dec 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of r-(-)-gossypol acetic acid in chronic lymphocytic leukemia (CLL), sponsored by Mayo Clinic. Started Jul 2015; status: terminated.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01003769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003769.